2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Factor VIII

Factor VIII

Coagulation factor VIII; FVIII

Factor VIII (FVIII) is an essential blood coagulation protein, is a key component of the fluid phase blood coagulation system. Factor VIII is also a large procoagulant glycoprotein and a metal ion-dependent heterodimer that circulates in plasma in a noncovalent complex with von Willebrand factor. Factor VIII absence causes a severe bleeding disorder.

Factor VIII Related Products (10):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9940
    Emicizumab
    		99.91%
    Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.
    Emicizumab
  • HY-P991694
    Latarcibart
    Latarcibart is an anti-protein S monoclonal antibody.Latarcibart can be used for the research of bleeding disorders.
    Latarcibart
  • HY-P99769
    Omfiloctocog alfa
    Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A.
    Omfiloctocog alfa
  • HY-P9940A
    Emicizumab (Anti-F9 & Factor IX)
    		Inhibitor 99.69%
    Emicizumab (Anti-F9 & Factor IX) is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab (Anti-F9 & Factor IX) can be used for hemophilia A research.
    Emicizumab (Anti-F9 & Factor IX)
  • HY-112998
    Efmoroctocog alfa
    Efmoroctocog alfa is a recombinant factor VIII-Fc fusion protein (rFVIIIFc). In mice with hemophilia A, Efmoroctocog alfa provides longer-lasting protection against tail vein transection injury than conventional rFVIII products. In dogs with hemophilia A, Efmoroctocog alfa produces a longer duration of improvement in whole blood clotting time than conventional rFVIII products. Efmoroctocog alfa can be used for research on hemophilia A.
    Efmoroctocog alfa
  • HY-160824
    Neutrophil elastase-IN-7
    		Inhibitor
    Neutrophil elastase-IN-7 (Compound 12) is an effective inhibitor of neutrophil elastase (HNE), with an IC50 value of 0.54 μM. Neutrophil elastase-IN-7 also exhibits significant inhibitory activity against various coagulation proteins, with the IC50 values for thrombin, FXa, FXIa, and FXIIIa being 8.2, 12.7, 1.2, and 5.7 μM, respectively. Neutrophil elastase-IN-7 can be used for research on inflammation, innate immune responses, and tissue remodeling.
    Neutrophil elastase-IN-7
  • HY-114128
    Turoctocog alfa pegol
    Turoctocog alfa pegol is a recombinant coagulation factor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa pegol can be used for researching haemophilia A.
    Turoctocog alfa pegol
  • HY-162654
    FXIIIa-IN-1
    		Inhibitor
    FXIIIa-IN-1 (Compound 16) is a potent and selective FXIIIa (Factor XIIIa) inhibitor with an IC50 value of 2.4 μM. FXIIIa-IN-1 inhibits FXIIIa by competing with the Gln-donor protein substrate (dimethylcasein). FXIIIa-IN-1 holds promise for the development of effective and safe novel anticoagulants.
    FXIIIa-IN-1
  • HY-P991516
    TB-402
    		Inhibitor
    TB-402, a human IgG4 anticoagulant monoclonal antibody, is a partial Factor VIII inhibitor. TB-402 has a prolonged antithrombotic effect. TB-402 can be used for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR).
    TB-402
  • HY-112865
    Octocog alfa
    Octocog alfa (ADVATE; BAY 81-8973; Kovaltry) is a standard half-length recombinant coagulation factor FVIII replacement therapy that also functions as a thrombin generation modulator. Octocog alfa regulates thrombin generation-related parameters in vitro and is used in studies related to severe hemophilia A.
    Octocog alfa